Pfizer Inc

PFE

New York Stock Exchange. Currency in USD

51.36 -0.04 ( -0.08% )

Real time prices: December 19

Market Cap.
288.30B
Beta (5Y monthly)
0.65
Price/Earnings
7.94
EPS (TTM)
6.52
Forward Dividend
1.64 (3.01%)
Ex-Dividend Date
Jan 26, 2023
Volume
16.00M
1y Target Est.
54.78
Day's Range
50.70
-
51.81
52 Week's Range
41.45
-
56.32

Historical Summary

Performance
EPS growth
Share Buybacks

About Pfizer Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.pfizer.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
5.61B
Employees
79000
Address
235 East 42nd Street, New York, NY, United States, 10017
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest news

Top Research Reports for Berkshire Hathaway, Exxon Mobil & Pfizer
Top Research Reports for Berkshire Hathaway, Exxon Mobil & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc....
By Zacks Investment Research - 6 weeks ago

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant,...
By Zacks Investment Research - 6 weeks ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on...
By Zacks Investment Research - 6 weeks ago

This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots
This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots

A strategy of holding stocks that have been on an upswing has outperformed the S&P...
By MarketWatch - 6 weeks ago

Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'

Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be...
By Benzinga - 7 weeks ago

Why Pfizer Stock Is Riskier Than AbbVie
Why Pfizer Stock Is Riskier Than AbbVie

Pfizer has a lot more revenue at risk over the next several years than AbbVie...
By The Motley Fool - 7 weeks ago

2 Dividend Stocks That Could Double Your Return in 10 Years
2 Dividend Stocks That Could Double Your Return in 10 Years

Both companies should hurdle their patent cliff concerns.
By The Motley Fool - 7 weeks ago